Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort
Figure 5.Univariate and multivariate Cox regression analyses of mutations in 2 DDR genes in the MSKCC cohort. Survival curves representation of mutations in (A) ATM and (B) MRE11A.